Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA HSV-2 Vaccine in Healthy Adults
NCT07330440Phase 1Enrolling by invitation
- Sponsor
- Changchun BCHT Biotechnology Co.
- Start
- Oct 2025
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of LVRNA101 in genital herpes (4 arms), sponsored by Changchun BCHT Biotechnology Co. Primary endpoint: Safety Endpoints. Started Oct 2025; status: enrolling by invitation.
02
Drugs
LVRNA101
03
Conditions
genital herpes
Beyond the preview
Go deeper on NCT07330440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07330440.